



OncoPrint BRCA Assay GX

Enabling large genomic rearrangement detection in *BRCA1* and *BRCA2* genes in as little as 24 hours

The Ion Torrent™ OncoPrint™ BRCA Assay detects *BRCA* somatic and germline mutations from formalin-fixed, paraffin-embedded (FFPE) tissue and whole blood, and has been widely adopted in molecular pathology laboratories across the world and referenced in several publications [1–9]. In addition to the Ion GeneStudio™ S5 System, the assay is now available on the Ion Torrent™ Genexus™ System.

The OncoPrint BRCA Assay GX is now available on the Genexus System

- One-day specimen-to-report workflow, operated on Ion Torrent™ Genexus™ Software
- Unmatched ease of use with only two user touchpoints and 20 minutes of hands-on time

Robust, rapid, and consistent performance

- Fully verified on clinical research samples
- Based on proven Ion AmpliSeq™ technology
- Requires only 20 ng of DNA input
- 100% exonic coverage with large intronic flanking regions
- Detects large genomic rearrangement, such as large insertions and deletions (indels) and exon-level duplication and deletion, removing the need to employ multiple technologies
- Enables detection of all relevant variant types with high confidence



Exceptional performance

Figures 1, 2, and 3 demonstrate the exceptional performance of the Oncomine BRCA Assay. All exons are 100% covered, with an average of 64 bases of flanking sequence into the introns upstream and downstream of each exon, allowing for over 99% confidence of detecting 5% somatic variants across both genes. The uniformity and high read counts help ensure high sensitivity and accuracy of both somatic and germline mutation detection, demonstrated with different workflows and sequencers.




Figure 1. Superior accuracy in detecting somatic and germline variants, and high consistency, independent of the workflow. (A) Sensitivity and positive predictive value (PPV) for detecting single-nucleotide variants (SNV) and indels. Positive predictive value = true positives/total number of positives. Sensitivity = true positives/(true positives + false positives). **(B)** The percent of concordance for germline analysis and somatic cell analysis with the Ion GeneStudio S5 and Genexus systems.




Figure 2. Relative abundance of BRCA exons is plotted. Shown are the data from a sample that has a deletion in *BRCA1* (gold) of exons 22 and 23 (red circle). *BRCA2* (green) has no copy number variation (CNV). The gray plot indicates the sample ID (sid) amplicons used for normalization.

Oncomine BRCA (5.16) Filter Chain Applied 95 of 103 Variants

Key Vari...	Type	Oncomine Gene Class	Oncomine Variant Class	Gene	Locus	AA Change	Ref	Alt	Call	Nuc Change	Allele Frequency (%)
Yes	snp	Loss-of-Function	Truncating	BRCA1	chr17:41234451	p.Arg1443Ter	G	A	PRESENT (HETEROZYGOUS)	c.4327C>T	31.6
Yes	del	Loss-of-Function	Truncating	BRCA2	chr13:32913558	p.Lys1691AsnfsTer15	CA	C	PRESENT (HETEROZYGOUS)	c.5073delA	35.7
Yes	ins	Loss-of-Function	Truncating	BRCA2	chr13:32937354	p.Ile2675AspfsTer6	T	TA	PRESENT (HETEROZYGOUS)	c.8021_8022insA	11.1
Yes	del	Loss-of-Function	Truncating	BRCA2	chr13:32913836	p.Asn1784ThrfsTer7	CAA	CA	PRESENT (HETEROZYGOUS)	c.5351delA	44.4

Figure 3. Example of a Genexus System report showing the results for a sample with an SNV on the BRCA1 gene, and two deletions and one insertion on the BRCA2 gene.

References

1. Valtcheva N, Nguyen-Sträuli BD, Wagner U, Freiburger SN, Varga Z, Britschgi C, Dedes KJ, Rechsteiner MP. Setting a diagnostic benchmark for tumor *BRCA* testing: detection of *BRCA1* and *BRCA2* large genomic rearrangements in FFPE tissue - A pilot study. *Exp Mol Pathol*. 2021 Dec;123:104705. doi: 10.1016/j.yexmp.2021.104705. Epub 2021 Oct 9. PMID: 34637782.
2. Germani A, Libi F, Maggi S, Stanzani G, Lombardi A, Pellegrini P, Mattei M, De Marchis L, Amanti C, Pizzuti A, Torrisi MR, Piane M. Rapid detection of copy number variations and point mutations in *BRCA1/2* genes using a single workflow by ion semiconductor sequencing pipeline. *Oncotarget*. 2018 Sep 14;9(72):33648-33655. doi: 10.18632/oncotarget.26000. PMID: 30263092; PMCID: PMC6154752.
3. Fumagalli C, Rappa A, Casadio C, Betella I, Colombo N, Barberis M, Guerini-Rocco E. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. *J Clin Pathol*. 2020 Mar;73(3):168-171. doi: 10.1136/jclinpath-2019-206127. Epub 2019 Sep 19. PMID: 31537627.
4. Shin S, Kim Y, Chul Oh S, Yu N, Lee ST, Rak Choi J, Lee KA. Validation and optimization of the Ion Torrent S5 XL sequencer and OncoPrint workflow for *BRCA1* and *BRCA2* genetic testing. *Oncotarget*. 2017 May 23;8(21):34858-34866. doi: 10.18632/oncotarget.16799. PMID: 28422718; PMCID: PMC5471017.
5. Gezirici A, Gökpinar İli E, Değirmenci B, Aydın Gümüş A, Özdemir G, Erman NA, Yavaş C. Hereditary Breast-Ovarian Cancer and *BRCA1/BRCA2* variants: a single center experience. *Acta Oncologica Turcica*. 2021 54(3), 264-272.
6. Lee A, Kang J, Lee H, Lee YS, Choi YJ, Lee KH, Nistala GJ, Scafe CR, Choi J, Yoo J, Han M D E, Kim Y, Kim M. *BRCA1/2* somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients. *Pathol Res Pract*. 2019 Nov 215(11):152595. doi: 10.1016/j.prp.2019.152595. Epub 2019 Aug 16. PMID: 31570282.
7. Hirotsu Y, Ooka Y, Sakamoto I, Nakagomi H, Omata M. Simultaneous detection of genetic and copy number alterations in *BRCA1/2* genes. *Oncotarget*. 2017 Dec 6;8(70):114463-114473. doi: 10.18632/oncotarget.22962. PMID: 29383094; PMCID: PMC5777706.
8. Ji G, Bao L, Yao Q, Zhang J, Zhu X, Bai Q, Shao Z, Yang W, Zhou X. Germline and tumor *BRCA1/2* pathogenic variants in Chinese triple-negative breast carcinomas. *J Cancer Res Clin Oncol*. 2021 Oct;147(10):2935-2944. doi: 10.1007/s00432-021-03696-2. Epub 2021 Jul 13. PMID: 34254208.
9. Bekos C, Grimm C, Kranawetter M, Polterauer S, Oberndorfer F, Tan Y, Müllauer L, Singer CF. Reliability of Tumor Testing Compared to Germline Testing for Detecting *BRCA1* and *BRCA2* Mutations in Patients with Epithelial Ovarian Cancer. *J Pers Med*. 2021 Jun 24;11(7):593. doi: 10.3390/jpm11070593. PMID: 34202525; PMCID: PMC8305542.

Ordering information

Product	Size	Cat. No.
For the Ion GeneStudio S5 System		
OncoPrint BRCA Research Assay, Manual Library Preparation	24 reactions	A32840
OncoPrint BRCA Research Assay, Chef-Ready Library Preparation	32 reactions	A32841
For the Genexus System		
OncoPrint BRCA Assay GX	32 reactions	A47912

Learn more at thermofisher.com/oncominebrca